33 Galactosaminogalactan and Pel are cationic heteropolysaccharides produced by the 34 opportunistic pathogens, Aspergillus fumigatus and Pseudomonas aeruginosa, 35 respectively. These exopolysaccharides both contain 1,4-linked N-acetyl-D-36 galactosamine and play an important role in biofilm formation by these organisms. 37 Proteins containing glycoside hydrolase domains have recently been identified within the 38 biosynthetic pathway of each exopolysaccharide. Recombinant hydrolase domains from 39 these proteins (Sph3 h from A. fumigatus and PelA h from P. aeruginosa) were found to 40 degrade their respective polysaccharides in vitro. We therefore hypothesized that these 41 glycoside hydrolases could exhibit anti-biofilm activity, and further, given the chemical 42 similarity between galactosaminogalactan and Pel, that they might display cross-species 43 activity. Treatment of A. fumigatus with Sph3 h disrupted A. fumigatus biofilms with an 44 EC 50 of 0.4 nM. PelA h treatment also disrupted pre-formed A. fumigatus biofilms with 45 EC 50 values similar to those obtained for Sph3 h . In contrast, Sph3 h was unable to disrupt 46 P. aeruginosa Pel-based biofilms, despite being able to bind to the exopolysaccharide. 47 Treatment of A. fumigatus hyphae with either Sph3 h or PelA h significantly enhanced the 48 activity of the antifungals posaconazole, amphotericin B and caspofungin, likely through 49 increasing antifungal penetration of hyphae. Both enzymes were non-cytotoxic and 50 protected A549 pulmonary epithelial cells from A. fumigatus-induced cell damage for up 51 to 24 hours. Intratracheal administration of Sph3 h was well tolerated, and reduced 52 pulmonary fungal burden in a neutropenic mouse model of invasive aspergillosis. These 53 findings suggest that glycoside hydrolases can exhibit activity against diverse 54 microorganisms and may be useful as therapeutic agents by degrading biofilms and 55 attenuating virulence. 56 57
(3, 4). Similarly, invasive aspergillosis is associated with mortality rates of up to 50% (5), 79 and increasing rates of antifungal resistance have been reported worldwide (6). These 80 factors underscore the urgent need for new effective therapies for these infections. 81 Although A. fumigatus and P. aeruginosa are members of different taxonomic 82 kingdoms, both produce biofilms that constitute a protective lifestyle for the organism. 83 Biofilms are complex communities of microorganisms that grow embedded in an 84 extracellular matrix composed of DNA, protein, and exopolysaccharide (7). Biofilm 85 formation provides a significant advantage to these organisms as the matrix mediates 86 adherence to host cells (8, 9) and aids in the resistance to both antimicrobial agents (10, 87 11) and host immune defences (12, 13) . A. fumigatus biofilm formation is dependent on 88 the cationic polysaccharide galactosaminogalactan (GAG), a heteroglycan composed of 89 α1,4-linked galactose and N-acetyl-D-galactosamine (GalNAc) that is partially 90 deacetylated (14, 15) . In comparison, P. aeruginosa has the genetic capacity to produce 91 three biofilm exopolysaccharides; alginate, Psl and Pel (16). GAG shares several 92 similarities with Pel, which has been identified as a cationic heteroglycan composed of 93 1,4-linked GalNAc and N-acetyl-D-glucosamine (GlcNAc) (17). Like GAG, the cationic 94 nature of Pel results from partial deacetylation of the polymer (17). Most clinical and 95 environmental isolates of P. aeruginosa utilize Pel and Psl during biofilm formation (18). 96
Alginate is dispensable for biofilm formation and is only observed in chronic pulmonary 97 infection when strains switch to a mucoid phenotype (18, 19) . 98 Strains of Aspergillus and P. aeruginosa with impaired GAG, or Pel and Psl 99 biosynthesis exhibit attenuated virulence (20, 21), suggesting that targeting these 100 exopolysaccharides may be a useful therapeutic strategy. We previously demonstrated 101 that recombinant glycoside hydrolases PelA h and PslG h , encoded in the pel and psl 102 operons of P. aeruginosa, respectively, target and selectively hydrolyze the Pel and Psl 103 exopolysaccharide components of the Pseudomonas biofilm matrix (22) . Treatment with 104 these enzymes rapidly disrupts established biofilms, increasing the susceptibility of P. 105 aeruginosa to human neutrophil killing and potentiation of the antibiotic colistin (22). 106
Our recent work on Aspergillus has identified a cluster of five genes, which 107 encode the proteins necessary for GAG biosynthesis (15). As with P. aeruginosa, we 108
found that the product of one of these genes contains a glycoside hydrolase domain, 109
Sph3 h , that is capable of hydrolyzing purified and cell wall-associated GAG (23). In the 110 present study we assessed the therapeutic potential of Sph3 h in disrupting fungal biofilms. 111 We establish that the exogenous addition of Sph3 h is capable of rapidly disrupting 112 existing biofilms of this organism at nanomolar concentrations. Fig. 1a ). Biofilm disruption 133 was associated with a marked reduction in hyphae-associated GAG as detected by lectin 134 staining ( Fig. 1b and c) and scanning electron microscopy (Fig. 1d) . A catalytic variant 135
Sph3 h D166A, which does not mediate GAG hydrolysis (23), displayed a greater than 136 500-fold reduction in anti-biofilm activity ( Fig. 1a ) and failed to mediate degradation of 137 biofilm-associated GAG (Fig. 1b and c hydrolyzing purified GAG (Fig. S2 ). Furthermore, using the crystal violet biofilm assay, 150
we found that PelA h disrupted A. fumigatus fungal biofilms with an EC 50 value of 2.80 ± 151 1.14 nM (Fig. 2a ). The treatment of A. fumigatus hyphae with PelA h also resulted in a 152 reduction in the amount of cell wall-associated GAG ( Fig. 2b-d biofilms and did not degrade hyphae-associated GAG (Fig. 2b and c Δpsl P BAD pel. Treatment of these established biofilms with Sph3 h did not affect levels of 168 Pel within the biofilms as visualized by lectin staining (Fig. 3a and b) , nor did it reduce 169 biofilm biomass, even at concentrations exceeding 10 μM (Fig. 3c) . 170 Since Sph3 h did not hydrolyze Pel within P. aeruginosa biofilms, we tested whether the 171 enzyme was capable of recognizing and binding this polysaccharide. Using an ELISA-172 based binding assay we observed dose-dependent binding of Sph3 h to culture 173 supernatants from the Pel over-producing P. aeruginosa strain, but not from supernatants 174 of the Pel-deficient strain PAO1 ΔwspF Δpel Δpsl (Fig. 3d) . These data suggest that the 175 inability of Sph3 h to disrupt Pel-mediated biofilms is likely a consequence of an inability 176 to hydrolyze Pel rather than being unable to bind the polysaccharide. Dose-dependent 177 binding of the inactive Sph3 h D166A variant to GAG-containing culture supernatants was 178 also observed ( Fig. S3 ), suggesting that binding of hydrolases to exopolysaccharides is 179 insufficient to disrupt established biofilms in the absence of enzymatic cleavage of the 180 polymer. 181 182
Sph3 h and PelA h potentiate antifungals by enhancing their intracellular penetration. 183
The Pel polysaccharide enhances resistance to several antibiotics including 184 aminoglycosides and colistin (22, 24, 25). Since biofilm formation by A. fumigatus is 185 associated with increased resistance to a number of antifungal agents (26-28), we 186
hypothesized that GAG may have an analogous function to Pel in enhancing resistance to 187 antifungal agents. To test this hypothesis, we investigated whether Fluorometric studies revealed that Sph3 h -treatment resulted in higher accumulation of 202 BDP-PCZ within A. fumigatus hyphae (Fig. 4b) . This finding indicates that GAG protects 203
A. fumigatus from the action of lipophilic antifungals by limiting their penetration into 204 hyphae. 205 206
Recombinant Sph3 h and PelA h protect epithelial cells from damage by A. fumigatus. 207
A. fumigatus GAG-mediated adherence is required for A. fumigatus to damage A549 208 pulmonary epithelial cells in vitro (20). We therefore tested whether treatment with either 209
Sph3 h or PelA h could protect epithelial cells from fungal-induced injury using an 210 established chromium ( 51 Cr) release damage assay (30). We first established that the 211 enzymes were not cytotoxic and that the addition of Sph3 h or PelA h to uninfected A549 212 cell monolayers did not cause detectable cellular damage (Fig. S5a) , a finding verified 213
with the IMR-90 human lung fibroblast cell line (Fig. S5b) . These data are consistent 214 with the lack of cytotoxicity previously reported for PelA h (22). Next, we assessed 215
whether Sph3 h or PelA h were able to protect A549 cell monolayers from damage by A. 216
fumigatus. Sph3 h reduced epithelial cell injury by > 80% for 24 hours (Fig. 5a ).
217
Treatment with PelA h also protected epithelial cells from A. fumigatus-induced damage 218 (Fig. 5a) . The protective effect of PelA h was shorter than that observed with Sph3 h , and 219 was lost before 24 hours of treatment. The addition of protease inhibitors extended PelA h -220 mediated epithelial cell protection to 24 hours ( Fig. S5c ), suggesting that the decrease in 221
PelA h mediated protection was likely due to proteolytic degradation of the recombinant 222 protein. Epithelial cell protection was not observed with the catalytic variants, PelA h 223 E218A or Sph3 h D166A, suggesting that the hydrolytic activity of the enzymes is 224 required for protection (Fig 5a) .
226
Intratracheal Sph3 h is well tolerated, and attenuates fungal virulence in an 227
immunocompromised mouse model of pulmonary aspergillosis. Given the ability of 228 Sph3 h to protect epithelial cells for over 24 hours, this hydrolase was selected for 229 evaluation in vivo. BALB/c mice treated intratracheally with doses up to 500 μg of Sph3 h 230 exhibited no signs of stress, weight loss or change in body temperature post-treatment 231 ( Fig. S6a and b) . Additionally, no significant increase in pulmonary injury or 232 inflammation between treated and untreated mice were observed as measured by 233 bronchoalveolar lavage lactate dehydrogenase activity and total pulmonary leukocyte 234 populations ( Fig. 5b and Fig. S6c ). Collectively these results suggest that a single 235 intratracheal dose of Sph3 h is well tolerated by mice. 236
To determine the ability of Sph3 h to attenuate virulence of A. fumigatus, neutropenic 237 BALB/c mice were infected intratracheally with A. fumigatus conidia with or without the 238 co-administration of 500 μg of Sph3 h . Four days after infection, mice infected with A. 239
fumigatus and treated with Sph3 h had a significantly lower pulmonary fungal burden to 240 untreated, infected mice as measured by both fungal DNA ( Fig. 5c ) and pulmonary 241 galactomannan content (Fig. S7) . The fungal burden of the Sph3 h -treated mice was 242 similar to that observed with mice infected with the GAG-deficient hypovirulent strain 243
Δuge3 (20). Consistent with the fungal burden data, histopathologic examination of lung 244 sections revealed the presence of fungal lesions in untreated, infected mice, but no 245 detectable lesions in the lungs of infected mice treated with Sph3 h , or those infected with 246 conidia of the Δuge3 mutant (Fig. 5d ). These findings suggest that Sph3 h -mediated 247 degradation of GAG can limit the growth of A. fumigatus in vivo, to the same degree as is 248 observed with GAG-deficient organisms. 249 250
Discussion 251
In this study, we demonstrate that the fungal glycoside hydrolase Sph3 h is able to 252 degrade pre-formed A. fumigatus biofilms. This study is the first example of the use of a 253 glycoside hydrolase to disrupt a fungal biofilm. Further, we establish that the glycoside 254
hydrolase PelA h displays activity against biofilms formed by organisms across different 255 microbial kingdoms. Both glycoside hydrolases potentiated the penetration and activity of 256 antifungal agents in vitro, exhibited no toxicity against mammalian cells and protected 257 epithelial cells from A. fumigatus-induced damage. Pulmonary administration of Sph3 h 258 was well tolerated and limited fungal growth in an immunocompromised mouse model, 259
suggesting that these enzymes are promising therapeutic agents for the treatment of 260 fungal disease. 261
The mechanism by which the biofilm matrix enhances A. fumigatus resistance to 262
antifungals is poorly understood. work has suggested that Pel anchors eDNA within P. aeruginosa biofilms through 283 charge-charge interactions (17). Given the similarities between Pel and GAG, it is 284 possible that GAG-mediated binding of eDNA may also contribute to enhancing 285 antifungal resistance. 286
The results of these studies add to an emerging body of evidence that fungal 287 biofilms share structural (32-35) and functional (26, 36, 37) similarity with those formed 288 by pathogenic bacteria. The finding that glycoside hydrolases can display activity against 289 the exopolysaccharides and biofilms of both fungi and bacteria provides the first evidence 290 that these similarities could potentially be exploited for the development of therapeutics 291 active against both organisms. Additionally, the similarity between the 292 exopolysaccharides of P. aeruginosa and A. fumigatus, coupled with the interspecies 293 activity of their glycoside hydrolases suggest the intriguing possibility that 294 exopolysaccharide interactions may occur between organisms during multispecies 295 biofilm formation. Co-colonization with P. aeruginosa and A. fumigatus is not 296 uncommon in patients with chronic pulmonary disease such as cystic fibrosis (38). 297
Although studies of the formation of mixed fungal-bacterial biofilms during pulmonary 298 infection are limited, a recent study of patients with chronic lung disease reported that 299 antibacterial therapy for P. aeruginosa was associated with a reduction in fungal 300
colonization, suggesting the possibility of microbial cooperation (39). Further studies 301 examining the role of cross-species exopolysaccharide and exopolysaccharide-modifying 302 enzyme interactions are required to establish a role for cooperative biofilm interactions in 303 pulmonary disease. 304
While PelA h exhibited cross-species activity and disrupted pre-formed fungal 305 biofilms, Sph3 h bound Pel, but was unable to disrupt established Pel-mediated biofilms. 306
This difference in activity may reflect differences in the composition or conformation of 307 each polysaccharide since GAG is a heteropolymer of GalNAc and galactose while Pel is 308 comprised of GalNAc and GlcNAc. It is likely that these differences influence the ability 309
of Sph3 h and PelA h to hydrolyze the polymer. The inability of Sph3 h to degrade pre-310
formed P. aeruginosa biofilms may suggest that mature Pel adopts a configuration or 311 undergoes post-synthetic modification that renders it incompatible with the catalytic 312 active site of Sph3 h and resistant to cleavage. Detailed studies of these enzymes to 313 determine the mechanisms underlying their differential activity against Pel will require 314 purified polysaccharide, which is currently not available. 315
Both Sph3 h and PelA h were found to be non-cytotoxic, and a single dose of 316
intratracheal Sph3 h was well tolerated by BALB/c mice. Co-administration of Sph3 h with 317 wild-type conidia to neutropenic mice greatly reduced fungal outgrowth within the lungs 318 of these mice. Together these results provide proof-of-concept that the glycoside 319 hydrolases can be used to improve the outcome of fungal infection, with minimal side 320 effects and toxicity. These findings will pave the way for future work to evaluate the 321 utility of these agents as antifungal therapeutics including detailed pharmacokinetic and 322 toxicity studies, as well as the evaluation of these enzymes for the treatment of 323 established fungal infections alone and in combination therapy with lipophilic antifungal 324 agents such as posaconazole or amphotericin B. 325 326
Methods 327
Strains and culture conditions. Strains used in this study are detailed in Table S1 and 328 detailed culture conditions are described in the Supplementary Information (SI). 329
Recombinant hydrolase expression and purification. Hydrolases were expressed and 330 purified as described previously (22, 23). 331
Treatment of A. fumigatus with glycoside hydrolases. To visualize the effects of 332 hydrolases on cell wall-associated GAG, hyphae were treated with recombinant 333 hydrolases and stained with fluorescein-conjugated soybean agglutinin as previously 334 described (23), with minor modifications. Hyphae were counterstained with a 1:1000 335 dilution of DRAQ5 (eBioscience) in phosphate buffered saline (PBS) for 5 min prior to 336 paraformaldehyde (PFA) fixation. Complete image acquisition and processing methods 337 can be found in the SI. To study the effects of hydrolases on biofilms, 10 4 conidia were 338 grown in Brian media in polystyrene, 96-well plates for 19 h at 37 °C and 5% CO 2 and 339 then treated with the indicated concentration of glycoside hydrolase in PBS for 1 h at 340 room temperature. Biofilms were then gently washed, stained with 0.1% (w/v) crystal 341 violet and de-stained with 100% ethanol for 10 min. The optical density of the de-stain 342 fluid was measured at 600 nm (OD 600 ). 343
Scanning electron microscopy. Conidia were grown for 9 h in Dulbecco's Modified 344
Eagle's Medium (DMEM) at 37 °C, 5% CO 2 on glass coverslips, washed once with 345
Ham's F-12K (Kaighn's) Medium, and incubated with 500 μL in F-12K Medium with or 346 without 0.5 μM hydrolase for 3 h at 37°C, 5% CO 2 . Coverslips were processed for 347 scanning electron microscopy as previously described (20) for 90 min at 37 °C, 5% CO 2 then exposed to 2 μg/mL BDP-PCZ for 10 mins. The plate 386 was then read using an Infinite M1000 fluorescent plate reader with excitation 387 wavelengths of 532 and 488 nm for RFP and BDP-PCZ, respectively. Background 388 fluorescence was subtracted from both RFP and BDP-PCZ signals and the BDP-PCZ 389 signal was then normalized to total RFP fluorescence for each well. Female BALB/c mice 5-6 weeks of age were anaesthetized with isoflurane and 397 administered a single endotracheal injection of 500 μg Sph3 h in 50 μL PBS and 398 monitored daily for 7 days. Mice were then euthanized by CO 2 overdose and their 399 airways lavaged with 1 mL PBS that was administered and collected through a needle 400 inserted in the trachea. A total of 2 lavages were performed and pooled. The presence of 401 LDH in the BAL fluid was used as an indicator of pulmonary damage; LDH activity was 402 measured in the fluid using a commercial assay (Promega), as per manufacturer's 403
instructions. 404
Effects of Sph3 h in a severely immunocompromised mouse model of invasive 405 pulmonary aspergillosis. Mice were immunosuppressed with cortisone acetate and 406 cyclophosphamide as previously described (20, 41). Mice were infected with an 407 endotracheal injection of 5x10 3 A. fumigatus conidia, resuspended in either PBS alone, or 408
in combination with 500 μg of Sph3 h . Mice were monitored daily and moribund animal 409 were euthanized. At 4 days post infection mice were euthanized and their lungs were 410
harvested. For fungal burden analysis, lungs were homogenized in 5 mL PBS containing 411 protease inhibitor cocktail (Roche), and aliquots were stored at -80°C until use. 412
Pulmonary fungal burden was determined as previously described (15), and detailed in 413 the SI. For histological examination, lungs were inflated with 10% buffered formalin 414 (Fisher Scientific) and immersed in formalin overnight to fix. Lungs were then embedded 415 in paraffin and 4 μm thick sections were stained with periodic acid Schiff (PAS) stain. 416 417
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